The key roles of complement and tissue factor in Escherichia coli-induced coagulation in human whole blood

Clinical and Experimental Immunology

Volumn 182, Issue 1, 2015, Pages 81-89

  Landsem, A ^a,b   Fure, H ^a   Christiansen, D ^a   Nielsen, E W ^b,c   Osterud B ^b   Mollnes, T E ^a,b,d,e   Brekke, O L ^a,b  

^a NORDLAND HOSPITAL   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c NORD UNIVERSITY   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

CD14; Coagulation; Complement; Escherichia coli; Lipopolysaccharide; Sepsis; Whole blood

Indexed keywords

BLOOD CLOTTING FACTOR; CD14 ANTIGEN; CD14 F(AB')2 FRAGMENT ANTIBODY; COMPLEMENT; COMPLEMENT COMPONENT C3; COMPLEMENT FACTOR; COMPLEMENT INHIBITOR; COMPSTATIN; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN F(AB')2 FRAGMENT; LEPIRUDIN; MESSENGER RNA; PENTRAXIN 3; PROTHROMBIN; PROTHROMBIN FRAGMENT F 1+2; THROMBOPLASTIN; UNCLASSIFIED DRUG; ANTITHROMBIN; C REACTIVE PROTEIN; CYCLOPEPTIDE; HIRUDIN DERIVATIVE; LIPOPOLYSACCHARIDE; PEPTIDE FRAGMENT; PROTHROMBIN FRAGMENT 1.2; RECOMBINANT PROTEIN; SERUM AMYLOID P;

ARTICLE; BLOOD CLOTTING; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MONOCYTE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; UPREGULATION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; GENETICS; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; SEPSIS;

ANTIGENS, CD14; ANTITHROMBINS; BLOOD COAGULATION; C-REACTIVE PROTEIN; COMPLEMENT C3; ESCHERICHIA COLI; HIRUDINS; HUMANS; LIPOPOLYSACCHARIDES; PEPTIDE FRAGMENTS; PEPTIDES, CYCLIC; PROTHROMBIN; RECOMBINANT PROTEINS; RNA, MESSENGER; SEPSIS; SERUM AMYLOID P-COMPONENT; THROMBOPLASTIN; UP-REGULATION;

EID: 84941261381     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12663     Document Type: Article

References (31)

1. Skrupky LP, Kerby PW, Hotchkiss RS. Advances in the management of sepsis and the understanding of key immunologic defects. Anesthesiology 2011; 115:1349-62.
2. Mackman N. The many faces of tissue factor. J Thromb Haemost 2009; 7 (Suppl. 1):136-9.
3. Napoleone E, di Santo A, Peri G et al. The long pentraxin PTX3 up-regulates tissue factor in activated monocytes: another link between inflammation and clotting activation. J Leukoc Biol 2004; 76:203-9.
4. Mantovani A, Garlanda C, Doni A, Bottazzi B. Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. J Clin Immunol 2008; 28:1-13.
5. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 2013; 13:34-45.
6. Warr TA, Rao LV, Rapaport SI. Disseminated intravascular coagulation in rabbits induced by administration of endotoxin or tissue factor: effect of anti-tissue factor antibodies and measurement of plasma extrinsic pathway inhibitor activity. Blood 1990; 75:1481-9.
7. Chow JC, Young DW, Golenbock DT, Christ WJ, Gusovsky F. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem 1999; 274:10689-92.
8. Shimazu R, Akashi S, Ogata H et al. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 1999; 189:1777-82.
9. Ohto U, Fukase K, Miyake K, Satow Y. Crystal structures of human MD-2 and its complex with antiendotoxic lipid IVa. Science 2007; 316:1632-4.
10. Zanoni I, Granucci F. Role of CD14 in host protection against infections and in metabolism regulation. Front Cell Infect Microbiol 2013; 3:32.
11. Brekke OL, Christiansen D, Fure H, Fung M, Mollnes TE. The role of complement C3 opsonization, C5a receptor, and CD14 in E. coli-induced up-regulation of granulocyte and monocyte CD11b/CD18 (CR3), phagocytosis, and oxidative burst in human whole blood. J Leukoc Biol 2007; 81:1404-13.
12. Mollnes TE, Brekke OL, Fung M et al. Essential role of the C5a receptor in E. coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 2002; 100:1869-77.
13. Brekke OL, Waage C, Christiansen D et al. The effects of selective complement and CD14 inhibition on the E. coli-induced tissue factor mRNA upregulation, monocyte tissue factor expression, and tissue factor functional activity in human whole blood. Adv Exp Med Biol 2013; 735:123-36.
14. Mollnes TE, Christiansen D, Brekke OL, Espevik T. Hypothesis: combined inhibition of complement and CD14 as treatment regimen to attenuate the inflammatory response. Adv Exp Med Biol 2008; 632:253-63.
15. Barratt-Due A, Pischke SE, Brekke OL et al. Bride and groom in systemic inflammation - the bells ring for complement and Toll in cooperation. Immunobiology 2012; 217:1047-56.
16. Brekke OL, Christiansen D, Fure H et al. Combined inhibition of complement and CD14 abolish E. coli-induced cytokine-, chemokine- and growth factor-synthesis in human whole blood. Mol Immunol 2008; 45:3804-13.
17. Lappegard KT, Riesenfeld J, Brekke OL, Bergseth G, Lambris JD, Mollnes TE. Differential effect of heparin coating and complement inhibition on artificial surface-induced eicosanoid production. Ann Thorac Surg 2005; 79:917-23.
18. Morikis D, Assa-Munt N, Sahu A, Lambris JD. Solution structure of Compstatin, a potent complement inhibitor. Protein Sci 1998; 7:619-27.
19. Mollnes TE, Redl H, Hogasen K et al. Complement activation in septic baboons detected by neoepitope-specific assays for C3b/iC3b/C3c, C5a and the terminal C5b-9 complement complex (TCC). Clin Exp Immunol 1993; 91:295-300.
20. Engstad CS, Lia K, Rekdal O, Olsen JO, Osterud B. A novel biological effect of platelet factor 4 (PF4): enhancement of LPS-induced tissue factor activity in monocytes. J Leukoc Biol 1995; 58:575-81.
21. Lappegard KT, Christiansen D, Pharo A et al. Human genetic deficiencies reveal the roles of complement in the inflammatory network: lessons from nature. Proc Natl Acad Sci USA 2009; 106:15861-6.
22. Verbon A, Dekkers PE, Ten HT et al. IC14, an anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans. J Immunol 2001; 166:3599-605.
23. Weinstein SL, June CH, DeFranco AL. Lipopolysaccharide-induced protein tyrosine phosphorylation in human macrophages is mediated by CD14. J Immunol 1993; 151:3829-38.
24. Hellerud BC, Stenvik J, Espevik T, Lambris JD, Mollnes TE, Brandtzaeg P. Stages of meningococcal sepsis simulated in vitro, with emphasis on complement and Toll-like receptor activation. Infect Immun 2008; 76:4183-9.
25. Jaillon S, Bonavita E, Gentile S et al. The long pentraxin PTX3 as a key component of humoral innate immunity and a candidate diagnostic for inflammatory diseases. Int Arch Allergy Immunol 2014; 165:165-78.
26. Huttunen R, Hurme M, Aittoniemi J et al. High plasma level of long pentraxin 3 (PTX3) is associated with fatal disease in bacteremic patients: a prospective cohort study. PLOS ONE 2011; 6:e17653.
27. Inforzato A, Doni A, Barajon I et al. PTX3 as a paradigm for the interaction of pentraxins with the complement system. Semin Immunol 2013; 25:79-85.
28. Napoleone E, di Santo A, Bastone A et al. Long pentraxin PTX3 upregulates tissue factor expression in human endothelial cells: a novel link between vascular inflammation and clotting activation. Arterioscler Thromb Vasc Biol 2002; 22:782-7.
29. Han B, Haitsma JJ, Zhang Y et al. Long pentraxin PTX3 deficiency worsens LPS-induced acute lung injury. Intens Care Med 2011; 37:334-42.
30. Deban L, Russo RC, Sironi M et al. Regulation of leukocyte recruitment by the long pentraxin PTX3. Nat Immunol 2010; 11:328-34.
31. Huber-Lang M, Sarma JV, Zetoune FS et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 2006; 12:682-7.